Canntab Joins Australian Medical Cannabis Study for Fibromyalgia, Other Chronic Disorders

Canntab Joins Australian Medical Cannabis Study for Fibromyalgia, Other Chronic Disorders
Canntab Therapeutics will participate in a five-year study of cannabis-based therapies to treat fibromyalgia and other disorders that are unresponsive to treatment. The Canadian company also is launching a suite of oral cannabinoid therapies — derived from cannabis and acting on cannabinoid receptors — in Australia in partnership with Cann Global by the end of this year. "This deal is two years in the making and represents important milestones for our company," Larry Latowsky, CEO of Canntab, said in a press release. "It is the first observational clinical study that we are confident will support our vision of our product as unique, effective and the preferred cannabinoid delivery system for many medical symptoms and conditions."  Previous studies suggest that medical cannabis may alleviate pain and improve quality of life in fibromyalgia patients. Canntab has developed pill formulations (given once daily or with extended release) from two of the active chemi
Subscribe or to access all post and page content.